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ABSTRACT
Nucleic acid amplification testing (NAT) was recently recommended by Brazilian legisla-
tion and has been implemented at some blood banks in the city of São Paulo, Brazil, in an 
attempt to reduce blood-born transmission of human immunodeficiency virus (HIV) and 
hepatitis C virus. Objective: Manual magnetic particle-based extraction methods for HIV 
and HCV viral nucleic acids were evaluated in combination with detection by reverse transcriptase - 
polymerase chain reaction (RT-PCR) one-step. Methods: Blood donor samples were collected from 
January 2010 to September 2010, and minipools of them were submitted to testing. ELISA was used 
for the analysis of anti-HCV/HIV antibodies. Detection and amplification of viral RNA was 
performed using real-time PCR. Results: Out of 20.808 samples screened, 53 samples (29 for HCV 
and 24 for HIV) were confirmed as positive by serological and NAT methods. Conclusion: The man-
ual magnetic bead-based extraction in combination with real-time PCR detection can be used to 
routinely screen blood donation for viremic donors to further increase the safety of blood products.
Keywords: HCV; HIV; infection; reverse transcriptase polymerase chain reaction; blood banks.
INTRODUCTION
The risk of transfusion-transmitted hepatitis 
C virus (HCV) and human immunodeficiency 
virus (HIV) has progressively decreased dur-
ing the past few decades as a consequence of 
the introduction of several preventive meas-
ures. These include careful donor selection, 
repeat donors, enhanced donor questioning 
for eligibility and refinement of blood dona-
tion screening.1-3
The implementation of nucleic acid amplifi-
cation test (NAT), together with the existing anti-
gen/antibody-based assays for donor screening, 
has further reduced the residual risk of infection 
in the recipient by shortening the window phase. 
During this phase, an infected donor may har-
bor large amounts of infectious viral particles in 
the absence of serological markers and/or signs 
and symptoms of an ongoing infection.2-6
At present, single-donation testing is 
expensive,7 and in larger blood banks, it 
is not feasible due to the intensive workload. 
Dilution due to pool sampling and the need 
for the highest sensitivity has led to various 
methodological protocols for improvement 
of extraction efficiency, such as centrifuga-
tion8,9 or the addition of agents that support 
precipitation of viral particles.
Allain10 described a residual risk of viral 
transmission of less than 1:250,000 for HCV 
and 1:1.3 million for HIV in Europe and Unit-
ed States in the year 2000. After introduction of 
NAT for HCV and HIV, the residual risk was 
reduced to 1:2-4 million.
Stramer et al.2 reported NAT yield data 
from the first 4 years of NAT screening in the 
United States and concluded that the use of 
NAT prevented the transmission of approxi-
mately 5 cases of HIV-1 infections and 56 cases 
of HCV infections annually. 
In Brazil, the residual risk for HIV-1 mark-
ers in blood donors is higher than that in the 
United States. Sabino et al.11 and Wendel et 
al.12 described an estimate of 1.56 per 100,000 
donations following HIV antibody screening 
in repeat donors. Barreto et al.13 reported a re-
sidual risk for HIV of 4.1 per 1 million based 
on the incidence among first-time donors in 
São Paulo, Brazil. Using a less sensitive EIA has 
an NAT yield of 10.8 per 1 million donations 
based on published window periods.
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Brazilian legislation does not yet recommend the imple-
mentation of NAT screening for HIV and HCV. The Brazilian 
government has decided to create a commission to analyze 
the “advantages and disadvantages” before implementation of 
NAT,14 discussing the high cost of implementation of this test 
and the possible ways it could be used in the blood banks.
NAT technology has been implemented in our ser-
vice since October 2008, using minipool samples (n = 6, 
1.5 mL) for HIV/HCV, in a real-time PCR one-step test. In 
our laboratory (Colsan, São Paulo, Brazil), in the period of 
2005 to 2010, the median point estimates of residual risk 
of transfusion-transmitted infections were 1 per 93,227 for 
HCV and 1 per 97,940 for HIV.
The introduction of real-time PCR analysis has led to 
considerable progress in automating the amplification and de-
tection steps, but nucleic acid isolation remains laborious when 
performed manually. Compared with standard separation 
procedures, magnetic-separation techniques have several ad-
vantages, including simplicity in handling, a high automation 
potential and low cost.15
METHODS
Samples and standards
Samples from Colsan Blood Bank in São Paulo, Brazil, were 
tested for HIV and HCV with a NAT assay (DNA Tech-
nology of Brazil) by real-time PCR (Applied Biosystems) 
according to the manufacturer’s instructions. In parallel, 
anti-HIV and anti-HCV screening were performed by 
enzyme-linked immunosorbent assay (ELISA) testing, as 
determined by Brazilian legislation.
From January 1st, 2010 to September 30th, 2010, 20,808 
donations were enrolled in this study. Two hundred-fifty mi-
croliters of each serum sample were mixed in a serum pool 
of 6 samples. If a minipool was reactive for HIV and/or HCV, 
it was re-analyzed in individual reactions to determine the 
identity of the reactive donor. For individual tests, 300 µL 
were used as a sample.
Working reagents for nucleic acid amplification techniques 
from DNA Technology of Brazil were used to establish the ana-
lytical sensitivity of the multiplex assay.
Control reagents contained 100 IU/mL of the RNA HCV 
(genotypes 1-6) and HIV-1/2. Amplification of an internal con-
trol was included in every assay to exclude false negative results 
due to interference of inhibitors and to ensure the performance 
of the nucleic acid extraction procedure. 
RNA isolation by magnetic beads
Total RNA was extracted and purified using magnetic bead 
technology with the appropriate kit (Chemagic Viral DNA/
RNA kit). Pools of 0.250 mL of serum or plasma of each 
sample were centrifuged for 1 hour at 25.000 rcf to form 
the viral pellet, and then 0.100 mL of lysis buffer was added 
to each tube. The samples were vortexed and incubated at 
room temperature for 10 minutes.
Subsequently, 0.150 mL of the magnetic particles (magnet-
ic beads) were added and incubated at room temperature for 
20 minutes with agitation every 10 minutes (Figure 1A). The 
tubes were placed in a magnet specific to the separation of 
the magnetic beads containing the viral RNA, and the superna-
tant was removed (Figure 1B); 0.200 mL of wash solution was 
then added, and again the tubes were homogenized to wash the 
magnetic beads. The tubes were again transferred to the mag-
net to separate the beads containing the captured viral RNA. 
A second wash was performed with 0.150 mL, after which 
the beads were resuspended with 0.050 mL of elution buffer 
(Figure 1C). The isolated RNA (0.015 mL) was used in the real-
time PCR for the detection of viral RNA (HIV or HCV). 
After lysis, in a first step, magnetic beads with a specific 
functionalization are added to the biosuspension in order 
to bind the RNA target. Because of the small size of the par-
ticles, thorough mixing in the next step achieves very fast 
binding of the product. Subsequently, the loaded magnetic 
beads are retained selectively by magnetic separation and 
separated from the supernatant. Final washing and elution 
steps deliver the target product free from solids in a purified, 
often also concentrated form.
Reverse transcription
RNA was reverse transcribed into cDNA by the addition of 
Superscript III Platinum® One-Step in the mix containing 
all necessary reagents for amplification. Real-time amplifica-
tion was performed using a 7500 Real-Time Sequence De-
tection System (SDS; ABI Prism 7500; Applied Biosystems, 
CA, USA). Real-time PCR product accumulation was moni-
tored using a TaqMan probe. 
Quantitative real-time PCR
Relative gene expression was calculated using conditions at the 
early stages of PCR. At this point, amplification is logarithmic 
and can thus be correlated to the initial copy number of gene 
transcripts. Reactions were cycled 40 times under the condi-
tions previously determined by conventional PCR. At the end 
of PCR reaction, the temperature was increased from 60oC to 
Figure 1: The basic principle of viral isolation by magnetic 
beads.
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95oC at a rate of 2oC/min. During this time, fluorescence was 
measured every 15 s to construct a melting curve. A non-tem-
plated control was run with each assay. 
PCR was performed with commercial primers that are selec-
tive for HIV, HCV and an internal control (DNA Technology of 
Brazil). PCR was performed with primers HIV sense (5´ - TAA 
AGC TTG CCT TGA GTG CT - 3´), HIV antisense (5´- GTC 
TGA GGG ATC CTA GTT ACC AG - 3´), and probe HIV 
P (5´ - FAM - AGT AGT GTG GCC GTC TGT TGT GTG - 
3´) are located in the LTR region of HIV-1 genome Accession 
Number - HM583638. HCV sense (5´- CGG GAG AGC CAT 
AGT GGT 3´), HCV antisense (5´- CGC GAC CCA ACA CTA 
CTC – 3´) and probe HCV P (5´- FAM - TGC GGA ACC GGT 
GAG TAC ACC - 3´) Accession Number - HM594184.1
Enzyme-linked immunosorbent assay (ELISA)
Testing for HCV antibodies was performed with a third 
generation enzyme immunoassay (EIA-3; bioMérieux 
Co.) following the manufacturer’s instructions. S/CO ra-
tio (S, sample ratio and CO, cutoff ratio) was determined 
for all the blood samples and based on this we created two 
groups: Group A in which S/CO ratio was < 3, and group B 
in which S/CO ratio was > 3.16,17 That algorithm was devel-
oped in order to establish the relationship between S/CO 
ratio and the probability RT-PCR been positive.18
Amplification and detection
Fifteen microliters of eluate were used as a template for 
HCV/HIV RNA reverse transcription polymerase chain re-
action (RT-PCR), by a 7500 real-time PCR system (Applied 
Biosystems). The PCR amplification and detection was per-
formed according to the manufacturer’s instructions (DNA 
technology of Brazil). Internal controls monitored the valid-
ity of the PCR in each reaction. 
Statistical method
Kappa statistic was used to evaluate the agreement between 
tests.16 Kappa is calculated from the observed and expected 
frequencies on the diagonal of a square table of frequencies, 
with a 95% interval, used to study the reliability of nominal 
or categorical variables, where:
K = (po - pe) / (1 - pe)
k = kappa statistic 
po = proportion of observed agreement of diagnoses. 
pe = expected proportion of diagnostic agreement 
 due to chance
In this study, the kappa statistic should be interpret-
ed as the proportion of agreement between the two tests 
used beyond chance. In the case of perfect agreement, the 
value of Kappa = 1 (tests are consistent in all cases); Kappa 
is zero if the correlation is entirely due to chance, and nega-
tive when the correlation is lower than expected by chance. 
RESULTS
A total of 3,468 minipools, representing 20,808 blood dona-
tions were tested simultaneously by ELISA and NAT. All pools 
that tested negative for the presence of these viral sequences 
were in accordance with results obtained from serological rou-
tine screening. In the period studied, were obtained 29 samples 
positive for anti-HCV and 24 samples positive for anti-HIV. All 
samples were also detected by NAT. No samples were positive 
to anti-HCV/HIV and negative by NAT (Table 1). All of the 
Table 1. Samples tested for HCV/HIV NAT – Colsan (Associação Beneficente de Coleta de Sangue)
Period Number of samples Number of positive Number of positive 
 tested in minipool samples to HIV RNA samples to HCV RNA 
  and anti-HIV and anti-HCV
January 2010 2.421 0 4
February 2010 2.193 1 3
March 2010 4.472 2 4
April 2010 1.838 0 0
May 2010 1.628 3 2
June 2010 2.033 3 5
July 2010 2.153 6 4
August 2010 2.240 4 2
September 2010 1.830 5 5
Total 20.808  24 29 
Kappa = 0.99.
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results were validated by the internal positive control (IPC). 
There was almost perfect agreement (Kappa > 0.99) accord-
ing to the classification of Landis et al.17
DISCUSSION
Transfusion safety is one of the major concerns in the blood 
bank setting. In the past 30 years, great progress towards 
safer transfusions was made, especially concerning trans-
mission of viruses. Such strides were made due to the 
adoption of good manufacturing practices, better donor 
screening policies, an increase of repeat donors, and new 
technologies used in determining the biological qualifica-
tion of donors.
The NAT was first described in 1985 and began to be 
used in the screening of plasma products. In the late 1990s, 
Europe and the USA started screening blood donations for 
HIV and HCV. Now, it is well established that implementa-
tion of NAT is a crucial step to further reduce the residual 
risk of transfusion-transmitted diseases, notably HIV and 
HCV, to produce a safer blood inventory.
Although the introduction of real-time PCR has led to 
considerable progress in automating the amplification and 
detection steps of NAT, nucleic acid isolation remains very 
labor-intensive when performed manually. Traditional 
phenol-chloroform extraction and ethanol precipitation 
methods are complicated, time-consuming, hazardous, 
and unsuitable for processing high numbers of samples.
Several methods of nucleic acid isolation have been de-
veloped, i.e., extraction based on the method described by 
Boom,19 which uses the principle of adsorption of nucleic 
acids to silica matrices in the presence of “chemotropic 
salts” and alcohol.20
According to the literature, the salt guanidine thiocy-
anate is one of the most powerful chemotropic agents and 
is commonly used in the Boom method.20 Guanidine thio-
cyanate has both RNase-inactivating and lysing properties 
for viral particles and cellular structures21,22 and promotes 
binding of nucleic acids to silica surfaces.23 The Boom 
method is most commonly implemented in conjunction 
with spin columns.
In this study, we used magnetic beads that bind nucleic ac-
ids to their proprietary magnetic polyvinyl alcohol-based parti-
cles. The bound nucleic acids are then transferred through the 
steps of the extraction process. This extraction technology has 
successfully been evaluated to screen for viral nucleic acids in 
routine blood donations.
Pichl et al.24 used a total of 102 minipools, represent-
ing approximately 612 blood donations that were replicated 
from routine NAT pools, to analyze for B19 (parvovirus) 
DNA, HBV DNA, and HAV (hepatitis A virus) RNA. In our 
study, 3,468 minipools representing 20,808 blood donations 
replicated from routine NAT pools were analyzed for HIV 
and HCV RNA.
Nine minipools were positive for HIV RNA, and 18 
were positive for HCV RNA. These minipools were bro-
ken out to determine which sample was reactive. All pools, 
positive and negative, were in agreement with results 
obtained from routine screening. All were valid due to a 
negative result for the IPC RNA, indicating that the tests 
are highly specific and reliable.
The limit of detection determined for Parvovirus B19 
by Pichl et al.24 was 875 IU/mL, 260 IU/mL for HAV and 
1274 IU/mL for HBV. In our study, the detection limit for 
HCV and HIV was 100 IU/mL.
Hourfar et al.25 compared two methods of extraction: 
using a kit for extraction by silica column (QIAamp) and 
another by magnetic beads. The detection limit was 23.1 IU 
for HIV-1 and 10.7 IU of HCV per PCR for the bead extrac-
tion and 21.6 IU for HIV-1 per PCR and 5.4 IU for HCV per 
PCR for the QIAamp extraction (Qiagen).
Jarvis et al.26 uses the “decant” method on NucliSens au-
tomated extractor systems (bioMérieux UK Ltd., Basingstoke, 
UK) to extract nucleic acid from 2 mL plasma minipools as 
described by the manufacturer. The assays have 95% detection 
levels of 7.25 IU/mL for HCV and 39.8 IU/mL for HIV.
In our study, we observed that magnetic bead technology 
was very effective. The detection limits were 100 UI/mL, using 
minipools and duplex PCR reactions (Table 2).
EIA results are reported as “reactive” or “nonreactive,” and 
the EIA signal to cutoff (S/CO) ratio may also be reported as 
“high” or “low.” The EIA S/CO ratio is a comparison of the op-
tical density of the patient’s positive EIA result to the optical 
density of the laboratory’s positive EIA control. If the ratio is 
high (> 3.0 using the most widely employed ELISA diagnostic 
kits), the positive predictive value (that the patient really has 
HCV antibodies in the blood) of the patient’s result is high.
Albertoni et al.27 observed that 90% of the samples with an 
S/CO ratio of > 3 were positive in the RT-PCR test, confirming 
the serological tests; in contrast, 13% samples with S/CO ratio 
< 3 were confirmed as positive by RT-PCR. It was suggested 
that another 87% patients were false-positive by ELISA. In 
our study, we could see that all samples with S/CO < 3 were 
negative by RT-PCR, and samples with S/CO > 3 were con-
Table 2. Advantages and disadvantages between 
extraction methods RNA
 Silica Column Magnetics beads
Sample volume 0.140 mL 0.250 mL
Assay time 30 min  3 hours
Pool  No Yes
Limit detection 310 IU/mL 100 IU/mL
Cost/test US$ 13.00 US$ 6.00
Magnetic bead technology for viral RNA extraction from serum in blood bank screening
551Braz J Infect Dis 2011; 15(6):547-552
firmed positive by RT-PCR, indicating that there is indeed 
a strong relationship between the levels of HCV antibodies 
and HCV RNA. From the data obtained, it can be conclud-
ed that using magnetic beads for viral nucleic acid extrac-
tion from minipool samples is feasible as a manual process, 
shows high sensitivity, and offers the possibility to perform 
different PCR assays from one sample eluate.
It is important to note that, on average, the cost for the 
extraction of viral RNA by the column method is about 
$13.00 per test. However, when the magnetic beads are 
used for extraction, the cost is reduced by half. Therefore, 
it can be concluded that the magnetic bead technology for 
extraction of viral RNA is trustworthy, easy to perform, 
and cost-effective.
CONCLUSION
The manual magnetic bead-based extraction in combination 
with RT-PCR detection can be used routinely to screen blood 
donations for HIV and HCV viruses to further increase the 
safety of blood products.
In this study we noticed that the centrifugation for 1 hour 
of biological material to be analyzed has been crucial for the 
formation of the pellet for extraction of viral RNA. Moreover, 
it was extremely difficult to standardize the concentration of 
primers and probes in the multiplex assay (HIV + IPC) and 
(HCV + IPC)
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